Law Offices of Thomas J. Lamb

  • Free Case Evaluation
  • Mesothelioma & Asbestos Diseases
  • Legal Compensation
  • Asbestos Overview
  • Common Questions
  • About Our Firm

Recent Advances in Mesothelioma Treatment: Immunotherapy, Advanced Cell Therapy, and Other Innovative Therapeutic Modalities

February 19, 2025 By Thomas Lamb

Mesothelioma is a malignant condition arising from the pleura and peritoneum that is closely related to asbestos exposure [1]. Due to the prolonged time needed for one to fully develop mesothelioma, difficulty in diagnosing this condition early, its quick progression once manifested, and the limited [ mesothelioma treatment ] options, the prognosis … [Read more...]

Filed Under: Medicine, Mesothelioma Tagged With: mesothelioma, mesothelioma treatments

Treatment of Pleural Mesothelioma: ASCO Guideline Update

January 31, 2025 By Thomas Lamb

Since the initial [American Society of Clinical Oncologists (ASCO)] clinical practice guideline on the treatment of malignant pleural mesothelioma (PM) was published in 2018, considerable progress has been made which has changed not only the management but even the name of this disease. This guideline update focuses on four key areas: the role of … [Read more...]

Filed Under: Medicine, Mesothelioma Tagged With: malignant pleural mesothelioma (MPM), mesothelioma treatments, pleural mesothelioma

Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline

November 15, 2024 By Thomas Lamb

Introduction The purpose of this guideline is to provide recommendations for the management of patients with malignant pleural mesothelioma (MPM), an aggressive tumor with a poor prognosis. In the United States, about 3,000 new cases are diagnosed each year. The median overall survival of patients with advanced surgically unresectable disease is … [Read more...]

Filed Under: Medicine, Mesothelioma Tagged With: mesothelioma, mesothelioma diagnosis, mesothelioma treatments

Immunotherapy for Treatment of Pleural Mesothelioma: Current and Emerging Therapeutic Strategies

October 10, 2024 By Thomas Lamb

Pleural mesothelioma is a rare malignancy associated with asbestos exposure and very poor prognosis, with a 5-year overall survival of 12%. Outcomes may vary according to stage at time of diagnosis and histologic subtype. Most recently, clinical trials utilizing dual checkpoint inhibitor regimens and chemotherapy in combination with immune … [Read more...]

Filed Under: Medicine, Mesothelioma Tagged With: asbestos exposure, Immune checkpoint inhibitor (ICI), Immunotherapy, mesothelioma treatments, pleural mesothelioma

FDA Approves Pembrolizumab Plus Chemo for Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma

September 18, 2024 By Thomas Lamb

The FDA has approved [ Keytruda (pembrolizumab) ] plus pemetrexed and platinum chemotherapy in the frontline treatment of patients with unresectable advanced or metastatic malignant pleural mesothelioma. Data from the phase 2/3 KEYNOTE-483 study (NCT02784171) showed that [ Keytruda (pembrolizumab) ] plus chemotherapy (n = 222) significantly … [Read more...]

Filed Under: Medicine, Mesothelioma Tagged With: chemotherapy, Keytruda, malignant mesothelioma, malignant pleural mesothelioma (MPM), mesothelioma treatments, pembrolizumab, pemetrexed, pleural mesothelioma

Chemotherapy increases CDA expression and sensitizes malignant pleural mesothelioma cells to capecitabine treatment

September 5, 2024 By Thomas Lamb

Abstract:  The combination of cisplatin and pemetrexed remains the gold standard chemotherapy for malignant pleural mesothelioma (MPM), although resistance and poor response pose a significant challenge. Cytidine deaminase (CDA) is a key enzyme in the nucleotide salvage pathway and is involved in the adaptive stress response to chemotherapy. The … [Read more...]

Filed Under: Medicine, Mesothelioma Tagged With: chemotherapy, cisplatin, malignant pleural mesothelioma (MPM), mesothelioma treatments, pemetrexed

Integration of the PD-L1 inhibitor atezolizumab and WT1/DC vaccination into standard-of-care first-line treatment for patients with epithelioid malignant pleural mesothelioma—Protocol of the Immuno-MESODEC study

July 16, 2024 By Thomas Lamb

Abstract Malignant pleural mesothelioma (MPM) is an aggressive cancer with a very poor prognosis. Recently, immune checkpoint inhibition (ICI) has taken center stage in the currently ongoing revolution that is changing standard-of-care treatment for several malignancies, including MPM. As multiple arguments and accumulating lines of evidence are … [Read more...]

Filed Under: Medicine, Mesothelioma Tagged With: malignant pleural mesothelioma (MPM), mesothelioma treatments

Validation of Inflammatory Prognostic Biomarkers in Pleural Mesothelioma

April 16, 2024 By Thomas Lamb

Asbestos exposure is known as the main elicitor of pleural mesothelioma (PM) development. The pathology’s rarity, wide range of growth patterns, and devastating prognosis have hindered a standardized treatment to date. This study intended to determine possible prognosticators contributing to adjusting the treatment allocation. This initiated the … [Read more...]

Filed Under: Medicine, Mesothelioma Tagged With: mesothelioma, mesothelioma treatments, pleural mesothelioma

Impact of Surgery on Disease Progression and Survival of Patients with Pleural Mesothelioma

March 8, 2024 By Thomas Lamb

BACKGROUND:  The effects of surgery on the survival of patients with pleural mesothelioma remain poorly understood. We compared the therapeutic outcomes of patients receiving neoadjuvant chemotherapy followed by surgery or refusing surgery for pleural mesothelioma. METHODS:  This retrospective study included consecutive [ patients with pleural … [Read more...]

Filed Under: Medicine, Mesothelioma, Uncategorized Tagged With: meso, mesothelioma treatments, pleural mesothelioma

Pegargiminase Confers Survival Benefit in Nonepithelioid Pleural Mesothelioma

February 21, 2024 By Thomas Lamb

Adding pegargiminase to standard chemotherapy can improve outcomes in patients with chemotherapy-naïve, nonepithelioid pleural mesothelioma, according to research published in JAMA Oncology. [Szlosarek PW, Creelan BC, Sarkodie T, et al. Pegargiminase plus first-line chemotherapy in patients with nonepithelioid pleural mesothelioma. The ATOMIC-Meso … [Read more...]

Filed Under: Medicine, Mesothelioma Tagged With: mesothelioma, mesothelioma treatments, nonepithelioid pleural mesothelioma, Pegargiminase, pleural mesothelioma

Next Page »

Do I Have A Possible Case?

If you have a possible asbestos disease or mesothelioma lawsuit, you can get a free, confidential, and no obligation case review from asbestos lawyer Tom Lamb.

Main Navigation Menu

  • Asbestos Information Overview
  • NC Asbestos Exposure Sites
  • Asbestos Cancers / Diseases
  • Legal Compensation
  • Free Case Evaluation
  • About Our Law Firm
  • Attorney Tom Lamb
  • Recent News & Reports
  • Frequently Asked Questions
  • Sitemap

Attorney Tom Lamb

TJL@LambLawOffice.com

Phone: 800-426-9535

Lumina Station, Suite 225
1908 Eastwood Road
Wilmington, North Carolina

Please know that you can use our Quick Contact Form to tell us about your case.

Lamb Law Office Newsletter

Lamb Law Office Newsletter provides periodic updates about some of the cases that we are working on for clients, as well as an information resource you might find helpful.

Subscribe using Form below.

Subscription Form

* indicates required

Our Other Website

LambLawOffice.com

Contact Information

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, North Carolina 28403
910-256-2971 | 800-426-9535
TJL@LambLawOffice.com

  • Home
  • Disclaimer and Copyright Notices
  • Sitemap

Copyright © 2025 · Law Offices of Thomas J. Lamb, P.A.